The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The first of four planned modules at the new plant is expected to come online by summer 2026
The facility is expected to become operational by FY2028-29
The revenues this quarter are in line with the outlook we envisaged for the year
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Subscribe To Our Newsletter & Stay Updated
